Adding Zytiga and Prednisone to Regimen Is Effective in Treating High-Risk Prostate Cancer, Study Finds

Adding Zytiga and Prednisone to Regimen Is Effective in Treating High-Risk Prostate Cancer, Study Finds
Adding Zytiga (abiraterone acetate) plus prednisone to a regimen of radiotherapy and androgen deprivation therapy is effective in treating patients with high-risk prostate cancer, a Phase 2 clinical trial shows. The combination allows researchers to lower the duration of androgen deprivation therapy (ADT), which is associated with significantly increased toxicity when used long-term. The results were presented in an abstract titled, “Phase II trial of 6 months ADT/abiraterone acetate plus prednisone (AAP) and definitive radiotherapy (AbiRT) for men with intermediate to high risk localized prostate cancer,” at the 2018 Genitourinary Cancers Symposium, in San Francisco. Patients with high-risk prostate cancer, known as unfavorable prostate cancer, are recommended to undergo a combination of external beam radiotherapy (RT) and ADT — a regimen that has been shown to improve survival over just RT alone. Some recent data has suggested there may be benefits in adding Zytiga and prednisone to the RT/ADT regimen. This could then allow physicians to administer a shorter course of ADT treatment in men with aggressive, but localized, prost
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *